Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00260962
Status:
COMPLETED
Last Update Posted:
2018-01-30
First Post:
2005-11-30
Brief Title:
Olanzapine in the Treatment of Patients With Anorexia Nervosa
Sponsor:
Ottawa Hospital Research Institute
Organization:
Ottawa Hospital Research Institute
Study Overview
Official Title:
Olanzapine in the Treatment of Low Weight and Obsessional Thinking Among Those With Anorexia Nervosa A Double Blind Placebo Controlled Study
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication Olanzapine in achieving desired weight gain in patients identified as having Anorexia Nervosa either restricting or bingepurge subtype The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive andor anxiety symptoms associated with this disorder
Detailed Description:
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication Olanzapine in achieving desired weight gain in patients identified as having Anorexia Nervosa either restricting or bingepurge subtype The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive andor anxiety symptoms associated with this disorder
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-CA-O092 | OTHER | Eli Lilly | None |